journal article·2024-09Open access

Stabilization of TGF‐β Receptor 1 by a Receptor‐Associated Adaptor Dictates Feedback Activation of the TGF‐β Signaling Pathway to Maintain Liver Cancer Stemness and Drug Resistance

Kewei Liu, Fanxuan Tian, Xu Chen, Biyin Liu, Shuoran Tian, Yongying Hou, Lei Wang, Mengyi Han, Shiying Peng, Yuting Tan, Yuwei Pan, Zhaole Chu, Jinyang Li, Linrong Che, Dongfeng Chen, Liangzhi Wen, Zhongyi Qin, Xianfeng Li, Junyu Xiang, Xiu‐wu Bian, Qin Liu, Xiaoli Ye, Tao Wang, Bin Wang

Advanced Science· Volume 11· Issue 34

Abstract

Abstract Dysregulation of the transforming growth factor‐β (TGF‐β) signaling pathway regulates cancer stem cells (CSCs) and drug sensitivity, whereas it remains largely unknown how feedback regulatory mechanisms are hijacked to fuel drug‐resistant CSCs. Through a genome‐wide CRISPR activation screen utilizing stem‐like drug‐resistant properties as a readout, the TGF‐β receptor‐associated binding protein 1 (TGFBRAP1) is identified as a TGF‐β‐inducible positive feedback regulator that governs sensitivity to tyrosine kinase inhibitors (TKIs) and promotes liver cancer stemness. By interacting with and stabilizing the TGF‐β receptor type 1 (TGFBR1), TGFBRAP1 plays an important role in potentiating TGF‐β signaling. Mechanistically, TGFBRAP1 competes with E3 ubiquitin ligases Smurf1/2 for binding to TGFΒR1, leading to impaired receptor poly‐ubiquitination and proteasomal degradation. Moreover, hyperactive TGF‐β signaling in turn up‐regulates TGFBRAP1 expression in drug‐resistant CSC‐like cells, thereby constituting a previously uncharacterized feedback mechanism to amplify TGF‐β signaling. As such, TGFBRAP1 expression is correlated with TGFΒR1 levels and TGF‐β signaling activity in hepatocellular carcinoma (HCC) tissues, as well as overall survival and disease recurrence in multiple HCC cohorts. Therapeutically, blocking TGFBRAP1‐mediated stabilization of TGFBR1 by selective inhibitors alleviates Regorafenib resistance via reducing CSCs. Collectively, targeting feedback machinery of TGF‐β signaling pathway may be an actionable approach to mitigate drug resistance and liver cancer stemness.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: TGF-β signaling in diseases · Cancer Cells and Metastasis · Genetic factors in colorectal cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Engineering Research Center of Coptis Development and Utilization (Ministry of Education), School of Life Sciences Southwest University Chongqing 400715 P. R. China

Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital Army Medical University (Third Military Medical University) Chongqing 400042 P. R. China

School of Medicine Chongqing University Chongqing 400044 P. R. China

Department of Pathology Daping Hospital, Army Medical University (Third Military Medical University) Chongqing 400042 P. R. China

Institute of Pathology and Southwest Cancer Center, and Key Laboratory of Tumor Immunopathology of Ministry of Education of China, Southwest Hospital Army Medical University (Third Military Medical University) Chongqing 400038 P. R. China

Jinfeng Laboratory Chongqing 401329 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Natural Science Foundation of Chongqing Municipality · Army Medical University

References (51)

Show source-provided references
1. 10.1016/j.cell.2023.07.03610.1016/j.cell.2023.07.036 ↗
2. 10.1016/j.semcancer.2023.10.00410.1016/j.semcancer.2023.10.004 ↗
3. 10.1126/scisignal.aav518310.1126/scisignal.aav5183 ↗
4. 10.1038/s41467-021-21828-710.1038/s41467-021-21828-7 ↗
5. 10.1038/s41571-020-0403-110.1038/s41571-020-0403-1 ↗
6. 10.1016/j.stem.2018.11.01710.1016/j.stem.2018.11.017 ↗
7. 10.1016/j.ebiom.2019.09.02710.1016/j.ebiom.2019.09.027 ↗
8. 10.1016/j.cell.2012.10.03510.1016/j.cell.2012.10.035 ↗
9. 10.1038/s41388-022-02275-010.1038/s41388-022-02275-0 ↗
10. 10.1093/nar/gkac78010.1093/nar/gkac780 ↗
11. 10.1101/cshperspect.a02209510.1101/cshperspect.a022095 ↗
12. 10.1038/s41392-021-00781-310.1038/s41392-021-00781-3 ↗
13. 10.1186/s13046-021-02011-810.1186/s13046-021-02011-8 ↗
14. 10.1002/ijc.2586410.1002/ijc.25864 ↗
15. 10.1002/hep.2959810.1002/hep.29598 ↗
16. 10.1016/j.canlet.2018.11.03010.1016/j.canlet.2018.11.030 ↗
17. 10.1002/ijc.3297010.1002/ijc.32970 ↗
18. 10.3390/cancers1404094010.3390/cancers14040940 ↗
19. Chen Z. · Am. J. Cancer Res. · 2020 · 10 · 2993
20. 10.3390/curroncol2908043410.3390/curroncol29080434 ↗
21. 10.1016/j.jhep.2019.09.01010.1016/j.jhep.2019.09.010 ↗
22. 10.1158/1078-0432.CCR-14-195410.1158/1078-0432.CCR-14-1954 ↗
23. 10.1002/hep.2616810.1002/hep.26168 ↗
24. 10.1002/hep.2557010.1002/hep.25570 ↗
25. 10.1038/nature1413610.1038/nature14136 ↗
26. 10.1038/nprot.2017.01610.1038/nprot.2017.016 ↗
27. 10.1074/jbc.273.16.936510.1074/jbc.273.16.9365 ↗
28. 10.1074/jbc.M00647320010.1074/jbc.M006473200 ↗
29. Suh N. · Cancer Res. · 2003 · 63 · 1371
30. 10.1093/jmcb/mjz05710.1093/jmcb/mjz057 ↗
31. 10.1038/sj.onc.120788510.1038/sj.onc.1207885 ↗
32. 10.1042/BJ2004073810.1042/BJ20040738 ↗
33. 10.1016/S1097-2765(00)00134-910.1016/S1097-2765(00)00134-9 ↗
34. 10.26508/lsa.20190035010.26508/lsa.201900350 ↗
35. 10.1016/j.tibs.2022.06.00110.1016/j.tibs.2022.06.001 ↗
36. 10.1038/3936910.1038/39369 ↗
37. 10.15252/embj.202211280610.15252/embj.2022112806 ↗
38. 10.1016/j.cell.2015.01.04310.1016/j.cell.2015.01.043 ↗
39. 10.1126/science.aay181310.1126/science.aay1813 ↗
40. 10.1038/s41388-018-0480-010.1038/s41388-018-0480-0 ↗
41. 10.1038/bjc.2016.25510.1038/bjc.2016.255 ↗
42. 10.1016/j.stem.2009.08.01810.1016/j.stem.2009.08.018 ↗
43. 10.1038/srep2947910.1038/srep29479 ↗
44. 10.1172/JCI6541610.1172/JCI65416 ↗
45. 10.3389/fcell.2021.63977910.3389/fcell.2021.639779 ↗
46. 10.1038/s41418-018-0095-610.1038/s41418-018-0095-6 ↗
47. 10.1053/j.gastro.2024.01.02510.1053/j.gastro.2024.01.025 ↗
48. 10.1038/nm.443810.1038/nm.4438 ↗
49. 10.1007/s10120-020-01138-510.1007/s10120-020-01138-5 ↗
50. 10.1158/0008-5472.CAN-19-044210.1158/0008-5472.CAN-19-0442 ↗
51. 10.1002/advs.20230555010.1002/advs.202305550 ↗